| 1 |
Yin Z, Fang Q, Wen T, Zheng C, Fu C, Wang S, Li J, Gong X. Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China. Hum Vaccin Immunother 2023;19:2163813. [PMID: 36704960 DOI: 10.1080/21645515.2022.2163813] [Reference Citation Analysis]
|
| 2 |
Luo M, Zhou B, Reddem ER, Tang B, Chen B, Zhou R, Liu H, Liu L, Katsamba PS, Au KK, Man HO, To KK, Yuen KY, Shapiro L, Dang S, Ho DD, Chen Z. Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2. Emerg Microbes Infect 2023;12:2146538. [PMID: 36354024 DOI: 10.1080/22221751.2022.2146538] [Reference Citation Analysis]
|
| 3 |
Xia H, Yeung J, Kalveram B, Bills CJ, Chen JY, Kurhade C, Zou J, Widen SG, Mann BR, Kondor R, Davis CT, Zhou B, Wentworth DE, Xie X, Shi PY. Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages. Emerg Microbes Infect 2023;12:e2161422. [PMID: 36594261 DOI: 10.1080/22221751.2022.2161422] [Reference Citation Analysis]
|
| 4 |
Sun Q, Zeng J, Tang K, Long H, Zhang C, Zhang J, Tang J, Xin Y, Zheng J, Sun L, Liu S, Du X. Variation in synonymous evolutionary rates in the SARS-CoV-2 genome. Front Microbiol 2023;14. [DOI: 10.3389/fmicb.2023.1136386] [Reference Citation Analysis]
|
| 5 |
Lai J, Coleman KK, Tai SHS, German J, Hong F, Albert B, Esparza Y, Srikakulapu AK, Schanz M, Maldonado IS, Oertel M, Fadul N, Gold TL, Weston S, Mullins K, McPhaul KM, Frieman M, Milton DK. Exhaled Breath Aerosol Shedding of Highly Transmissible Versus Prior Severe Acute Respiratory Syndrome Coronavirus 2 Variants. Clin Infect Dis 2023;76:786-94. [PMID: 36285523 DOI: 10.1093/cid/ciac846] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 6 |
Gbaguidi GN, Aubert L, Schaeffer J, Fagour L, Dubremetz A, Enouf V, Glaudon-Louveau de la Guigneraye MH, Nestour F, Rosine J, Dos Santos G. Emergence and evolution of the Omicron SARS-CoV-2 variant in the island of Martinique. Infect Dis Now 2023;53:104690. [PMID: 36868476 DOI: 10.1016/j.idnow.2023.104690] [Reference Citation Analysis]
|
| 7 |
Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, Peacock SJ, Barclay WS, de Silva TI, Towers GJ, Robertson DL; COVID-19 Genomics UK Consortium. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol 2023;21:162-77. [PMID: 36653446 DOI: 10.1038/s41579-022-00841-7] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 8 |
Teyssou E, Marot S, Cocherie T, Fauchois A, Abdi B, Todesco E, Akhavan S, Pourcher V, Calvez V, Marcelin AG, Soulie C. Prolonged replication of BA.1 and BA.2 Omicron lineages compared to Delta variant in nasopharyngeal samples from COVID-19 patients. Infect Dis Now 2023;53:104629. [PMID: 36323397 DOI: 10.1016/j.idnow.2022.10.001] [Reference Citation Analysis]
|
| 9 |
Alidjinou EK, Demaret J, Corroyer-Simovic B, Vuotto F, Miczek S, Labreuche J, Goffard A, Trauet J, Lupau D, Dendooven A, Huvent-Grelle D, Podvin J, Dreuil D, Faure K, Deplanque D, Bocket L, Duhamel A, Sobaszek A, Hober D, Hisbergues M, Puisieux F, Autran B, Yazdanpanah Y, Labalette M, Lefèvre G. Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination. Clin Microbiol Infect 2023;29:258.e1-4. [PMID: 36257549 DOI: 10.1016/j.cmi.2022.10.014] [Reference Citation Analysis]
|
| 10 |
Liu Y, Peng H, Xiang T, Xu F, Jiang Y, Zhong L, Peng Y, Le A, Zhang W. Redistribution and activation of CD16brightCD56dimNK cell subset to fight against Omicron subvariant BA.2 after COVID-19 vaccination.. [DOI: 10.1101/2023.01.13.524025] [Reference Citation Analysis]
|
| 11 |
Mozaffer F, Cherian P, Krishna S, Wahl B, Menon GI. Effect of hybrid immunity, school reopening, and the Omicron variant on the trajectory of the COVID-19 epidemic in India: a modelling study. Lancet Reg Health Southeast Asia 2023;8:100095. [PMID: 36267800 DOI: 10.1016/j.lansea.2022.100095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 12 |
O'Keeffe JC, Constable M, Chiang J, Somerville M, Yerramilli A, Nolan R, Weeks G, O'Brien DP. Healthcare worker access to molnupiravir: A case series. PLoS One 2023;18:e0282695. [PMID: 36917596 DOI: 10.1371/journal.pone.0282695] [Reference Citation Analysis]
|
| 13 |
Osterman A, Badell I, Dächert C, Schneider N, Kaufmann AY, Öztan GN, Huber M, Späth PM, Stern M, Autenrieth H, Muenchhoff M, Graf A, Krebs S, Blum H, Czibere L, Durner J, Kaderali L, Baldauf HM, Keppler OT. Variable detection of Omicron-BA.1 and -BA.2 by SARS-CoV-2 rapid antigen tests. Med Microbiol Immunol 2023;212:13-23. [PMID: 36370197 DOI: 10.1007/s00430-022-00752-7] [Reference Citation Analysis]
|
| 14 |
Dhama K, Nainu F, Frediansyah A, Yatoo MI, Mohapatra RK, Chakraborty S, Zhou H, Islam MR, Mamada SS, Kusuma HI, Rabaan AA, Alhumaid S, Mutair AA, Iqhrammullah M, Al-Tawfiq JA, Mohaini MA, Alsalman AJ, Tuli HS, Chakraborty C, Harapan H. Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. J Infect Public Health 2023;16:4-14. [PMID: 36446204 DOI: 10.1016/j.jiph.2022.11.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 15 |
Migueres M, Mansuy JM, Vasseur S, Claverie N, Lougarre C, Soulier F, Trémeaux P, Izopet J. Omicron Wave SARS-CoV-2 Diagnosis: Evaluation of Saliva, Anterior Nasal, and Nasopharyngeal Swab Samples. Microbiol Spectr 2022;10:e0252122. [PMID: 36318040 DOI: 10.1128/spectrum.02521-22] [Reference Citation Analysis]
|
| 16 |
Tsang NNY, So HC, Cowling BJ, Leung GM, Ip DKM. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. Lancet Infect Dis 2022;23:421-34. [PMID: 36521506 DOI: 10.1016/S1473-3099(22)00732-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 17 |
Hansen C, Perofsky AC, Burstein R, Famulare M, Boyle S, Prentice R, Marshall C, McCormick BJJ, Reinhart D, Capodanno B, Truong M, Schwabe-Fry K, Kuchta K, Pfau B, Acker Z, Lee J, Sibley TR, McDermot E, Rodriguez-Salas L, Stone J, Gamboa L, Han PD, Duchin JS, Waghmare A, Englund JA, Shendure J, Bedford T, Chu HY, Starita LM, Viboud C. Trends in Risk Factors and Symptoms Associated With SARS-CoV-2 and Rhinovirus Test Positivity in King County, Washington, June 2020 to July 2022. JAMA Netw Open 2022;5:e2245861. [PMID: 36484987 DOI: 10.1001/jamanetworkopen.2022.45861] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 18 |
Kandel C, Lee Y, Taylor M, Llanes A, McCready J, Crowl G, Powis J, Li AX, Shigayeva A, Yip L, Katz K, Kozak R, Mubareka S, McGeer A. Viral dynamics of the SARS-CoV-2 Omicron Variant among household contacts with 2 or 3 COVID-19 vaccine doses. J Infect 2022;85:666-70. [PMID: 36283495 DOI: 10.1016/j.jinf.2022.10.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 19 |
Mastrorosa I, Cozzi-Lepri A, Colavita F, Lalle E, Mazzotta V, Cimaglia C, Paulicelli J, Matusali G, Fabeni L, Carletti F, Rosati S, Vita S, Giannico G, Piselli P, Biliotti E, Moghazi SA, Mosti S, Girardi E, Nicastri E, Garbuglia AR, Maggi F, Vaia F, Antinori A. SARS-CoV-2 nasopharyngeal viral load in individuals infected with BA.2, compared to Alpha, Gamma, Delta and BA.1 variants: A single-center comparative analysis. J Clin Virol 2022;157:105299. [PMID: 36183546 DOI: 10.1016/j.jcv.2022.105299] [Reference Citation Analysis]
|
| 20 |
Roohani J, Keikha M. Global challenge with the SARS-CoV-2 omicron BA.2 (B.1.1.529.2) subvariant: Should we be concerned? World J Virol 2022; 11(6): 496-501 [DOI: 10.5501/wjv.v11.i6.496] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 21 |
Valenzuela-Fernández A, Cabrera-Rodriguez R, Ciuffreda L, Perez-Yanes S, Estevez-Herrera J, González-Montelongo R, Alcoba-Florez J, Trujillo-González R, García-Martínez de Artola D, Gil-Campesino H, Díez-Gil O, Lorenzo-Salazar JM, Flores C, Garcia-Luis J. Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. Front Bioeng Biotechnol 2022;10:1052436. [PMID: 36507266 DOI: 10.3389/fbioe.2022.1052436] [Reference Citation Analysis]
|
| 22 |
Kurhade C, Zou J, Xia H, Liu M, Chang HC, Ren P, Xie X, Shi P. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster.. [DOI: 10.1101/2022.10.31.514580] [Reference Citation Analysis]
|
| 23 |
Qu P, Evans JP, Faraone J, Zheng YM, Carlin C, Anghelina M, Stevens P, Fernandez S, Jones D, Lozanski G, Panchal A, Saif LJ, Oltz EM, Xu K, Gumina RJ, Liu SL. Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2. bioRxiv 2022:2022. [PMID: 36299423 DOI: 10.1101/2022.10.19.512891] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 24 |
Kumar A, Sharma A, Vijay Tirpude N, Padwad Y, Sharma S, Kumar S. Perspective Chapter: Emerging SARS-CoV-2 Variants of Concern (VOCs) and Their Impact on Transmission Rate, Disease Severity and Breakthrough Infections. Infectious Diseases 2022. [DOI: 10.5772/intechopen.107844] [Reference Citation Analysis]
|
| 25 |
Alba JMG, Pérez-Martínez Z, Boga JA, Rojo-Alba S, de Oña JG, Alvarez-Argüelles ME, Rodríguez GM, Gonzalez IC, González IH, Coto E, García SM. Emergence of New SARS-CoV2 Omicron Variants after the Change of Surveillance and Control Strategy. Microorganisms 2022;10:1954. [PMID: 36296230 DOI: 10.3390/microorganisms10101954] [Reference Citation Analysis]
|
| 26 |
Wei Z, Ma W, Wang Z, Li J, Fu X, Chang H, Qiu Y, Tian H, Ge Y, Zhu Y, Xia A, Wu Q, Liu G, Zhai X, Zhang X, Wang Y, Zeng M. Household transmission of SARS-CoV-2 during the Omicron wave in Shanghai, China:a case-ascertained study.. [DOI: 10.1101/2022.09.26.22280362] [Reference Citation Analysis]
|
| 27 |
Yu CY, Wong SY, Liew NWC, Joseph N, Zakaria Z, Nurulfiza I, Soe HJ, Kairon R, Amin-nordin S, Chee HY. Whole genome sequencing analysis of SARS-CoV-2 from Malaysia: From alpha to Omicron. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1001022] [Reference Citation Analysis]
|
| 28 |
Jacobsen H, Katzmarzyk M, Higdon MM, Jiménez VC, Sitaras I, Bar-zeev N, Knoll MD. Post-vaccination neutralization responses to Omicron sub-variants.. [DOI: 10.1101/2022.09.16.22280017] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 29 |
Barroso da Silva FL, Giron CC, Laaksonen A. Electrostatic Features for the Receptor Binding Domain of SARS-COV-2 Wildtype and Its Variants. Compass to the Severity of the Future Variants with the Charge-Rule. J Phys Chem B 2022. [PMID: 36066414 DOI: 10.1021/acs.jpcb.2c04225] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 30 |
Konyak BM, Sharma M, Kharia S, Pandey RP, Chang C. A Systematic Review on the Emergence of Omicron Variant and Recent Advancement in Therapies. Vaccines 2022;10:1468. [DOI: 10.3390/vaccines10091468] [Reference Citation Analysis]
|
| 31 |
Uthman OA, Lyngse FP, Anjorin S, Hauer B, Hakki S, Martinez DA, Ge Y, Jonnerby J, Julin CH, Lin G, Lalvani A, Loss J, Madon KJ, Martinez L, Næss LM, Page KR, Prieto D, Robertson AH, Shen Y, Wurm J, Buchholz U. Susceptibility and infectiousness of SARS-CoV-2 in children versus adults, by variant (wild-type, Alpha, Delta): a systematic review and meta-analysis of household contact studies.. [DOI: 10.1101/2022.08.26.22279248] [Reference Citation Analysis]
|
| 32 |
Barnard RC, Davies NG, Jit M, Edmunds WJ; Centre for Mathematical Modelling of Infectious Diseases COVID-19 working group. Modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era. Nat Commun 2022;13:4879. [PMID: 35986002 DOI: 10.1038/s41467-022-32404-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 33 |
Hansen CL, Perofsky A, Burstein R, Famulare M, Boyle S, Prentice R, Marshall C, Mccormick BJ, Reinhart D, Capodanno B, Truong M, Schwabe-fry K, Kuchta K, Pfau B, Acker Z, Lee J, Sibley TR, Mcdermot E, Rodriguez-salas L, Stone J, Gamboa L, Han PD, Duchin JS, Waghmare A, Englund JA, Shendure J, Bedford T, Chu HY, Starita LM, Viboud C. Trends in risk factors and symptoms associated with SARS-CoV-2 and Rhinovirus test positivity in King County, Washington: A Test-Negative Design Study of the Greater Seattle Coronavirus Assessment Network.. [DOI: 10.1101/2022.08.12.22278203] [Reference Citation Analysis]
|
| 34 |
Patel RS, Agrawal B. Heterologous immunity induced by 1st generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine. Front Immunol 2022;13:952229. [DOI: 10.3389/fimmu.2022.952229] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 35 |
Li X, Tam AR, Chu W, Chan W, Ip JD, Chu AW, Abdullah SMU, Yip CC, Chan K, Wong SS, Cheng VC, Yuen K, Hung IF, To KK. Risk Factors for Slow Viral Decline in COVID-19 Patients during the 2022 Omicron Wave. Viruses 2022;14:1714. [DOI: 10.3390/v14081714] [Reference Citation Analysis]
|
| 36 |
Hawman DW, Meade-White K, Clancy C, Archer J, Hinkley T, Leventhal SS, Rao D, Stamper A, Lewis M, Rosenke R, Krieger K, Randall S, Khandhar AP, Hao L, Hsiang TY, Greninger AL, Gale M Jr, Berglund P, Fuller DH, Rosenke K, Feldmann H, Erasmus JH. Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine. EBioMedicine 2022;83:104196. [PMID: 35932641 DOI: 10.1016/j.ebiom.2022.104196] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 37 |
Lai J, Coleman KK, Sheldon Tai S, German J, Hong F, Albert B, Esparza Y, Srikakulapu AK, Schanz M, Maldonado IS, Oertel M, Fadul N, Gold TL, Weston S, Mullins K, Mcphaul KM, Frieman M, Milton DK. Evolution of SARS-CoV-2 Shedding in Exhaled Breath Aerosols.. [DOI: 10.1101/2022.07.27.22278121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 38 |
Ching W, Adhikari P, Jawad B, Podgornik R. Effect of Delta and Omicron mutations on the RBD-SD1 domain of the Spike protein in SARS-CoV-2 and the Omicron mutations on RBD-ACE2 interface complex.. [DOI: 10.1101/2022.07.28.501901] [Reference Citation Analysis]
|
| 39 |
Pappas G, Wallace M. Safe University in the Omicron Era: An Adaptable and Adjustable Protocol for the Operation of Universities during Epidemics Caused by Airborne Viruses. COVID 2022;2:983-1013. [DOI: 10.3390/covid2080074] [Reference Citation Analysis]
|
| 40 |
Medits I, Springer DN, Graninger M, Camp JV, Höltl E, Aberle SW, Traugott MT, Hoepler W, Deutsch J, Lammel O, Borsodi C, Puchhammer-stöckl E, Zoufaly A, Weseslindtner L, Aberle JH, Stiasny K. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections. Front Immunol 2022;13:946318. [DOI: 10.3389/fimmu.2022.946318] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 41 |
Townsley H, Carr EJ, Russell TW, Adams L, Mears HV, Bailey C, Black JR, Fowler AS, Wilkinson K, Hutchinson M, Harvey R, Clayton B, Kelly G, Beale R, Papineni P, Corrah T, Caidan S, Nicod J, Gamblin S, Kassiotis G, Libri V, Williams B, Gandhi S, Kucharski AJ, Swanton C, Wall EC, Bauer DL. Non-hospitalised, vaccinated adults with COVID-19 caused by Omicron BA.1 and BA.2 present with changing symptom profiles compared to those with Delta despite similar viral kinetics.. [DOI: 10.1101/2022.07.07.22277367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 42 |
Hegazy N, Cowan A, D’aoust PM, Mercier É, Towhid ST, Jia J, Wan S, Zhang Z, Kabir MP, Fang W, Graber TE, Mackenzie AE, Guilherme S, Delatolla R. Understanding the dynamic relation between wastewater SARS-CoV-2 signal and clinical metrics throughout the pandemic.. [DOI: 10.1101/2022.07.06.22277318] [Reference Citation Analysis]
|
| 43 |
Tiecco G, Storti S, Arsuffi S, Degli Antoni M, Focà E, Castelli F, Quiros-roldan E. Omicron BA.2 Lineage, the “Stealth” Variant: Is It Truly a Silent Epidemic? A Literature Review. IJMS 2022;23:7315. [DOI: 10.3390/ijms23137315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 44 |
Mozaffer F, Cherian P, Krishna S, Wahl B, Menon GI. Effect of hybrid immunity, school reopening, and the Omicron variant on trajectory of COVID-19 epidemic in India: A modelling study.. [DOI: 10.1101/2022.06.24.22276854] [Reference Citation Analysis]
|
| 45 |
Elliott P, Eales O, Steyn N, Tang D, Bodinier B, Wang H, Elliott J, Whitaker M, Atchison C, Diggle PJ, Page AJ, Trotter AJ, Ashby D, Barclay W, Taylor G, Ward H, Darzi A, Cooke GS, Donnelly CA, Chadeau-Hyam M. Twin peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England. Science 2022;376:eabq4411. [PMID: 35608440 DOI: 10.1126/science.abq4411] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 38.0] [Reference Citation Analysis]
|
| 46 |
Chotpitayasunondh T, Fisher DA, Hsueh P, Lee P, Nogales Crespo K, Ruxrungtham K. Exploring the Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Asia Pacific Countries and Territories: A Discussion Paper. IJTM 2022;2:275-308. [DOI: 10.3390/ijtm2030024] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 47 |
Barroso da Silva FL, Giron CC, Laaksonen A. Electrostatic features for the Receptor binding domain of SARS-COV-2 wildtype and its variants. Compass to the severity of the future variants with the charge-rule.. [DOI: 10.1101/2022.06.16.496458] [Reference Citation Analysis]
|
| 48 |
Morobe JM, Pool B, Marie L, Didon D, Lambisia AW, Makori T, Mohammed KS, de Laurent ZR, Ndwiga L, Mburu MW, Moraa E, Murunga N, Musyoki J, Mwacharo J, Nyamako L, Riako D, Ephnatus P, Gambo F, Naimani J, Namulondo J, Tembo SZ, Ogendi E, Balde T, Dratibi FA, Yahaya AA, Gumede N, Achilla RA, Borus PK, Wanjohi DW, Tessema SK, Mwangangi J, Bejon P, Nokes DJ, Ochola-Oyier LI, Githinji G, Biscornet L, Agoti CN. Genomic Epidemiology of SARS-CoV-2 in Seychelles, 2020-2021. Viruses 2022;14:1318. [PMID: 35746789 DOI: 10.3390/v14061318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 49 |
Park G, Kim S, Maeng J. Development and Evaluation of RT-LAMP Assays to Identify Variants of SARS-CoV-2.. [DOI: 10.1101/2022.06.16.496383] [Reference Citation Analysis]
|
| 50 |
Шиповалов А, Кудров Г, Старчевская М, Пьянков О. Характеристика штаммов генетических вариантов вируса SARS-CoV-2, выделенных на территории РФ в 2020-2022 гг (Обзор).. [DOI: 10.21055/preprints-3112090] [Reference Citation Analysis]
|
| 51 |
Van Goethem N, Chung PYJ, Meurisse M, Vandromme M, De Mot L, Brondeel R, Stouten V, Klamer S, Cuypers L, Braeye T, Catteau L, Nevejan L, van Loenhout JAF, Blot K. Clinical Severity of SARS-CoV-2 Omicron Variant Compared with Delta among Hospitalized COVID-19 Patients in Belgium during Autumn and Winter Season 2021-2022. Viruses 2022;14:1297. [PMID: 35746768 DOI: 10.3390/v14061297] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 52 |
Hoteit R, Yassine HM. Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. Vaccines (Basel) 2022;10:919. [PMID: 35746526 DOI: 10.3390/vaccines10060919] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 53 |
Li Y, Polotan FGM, Sotelo GIS, Alpino APA, Dolor AYM, Tujan MAA, Gomez MRR, Onza OJT, Chang AKT, Bautista CT, Carandang JC, Lim DR, Dancel LLM, Uy-lumandas M, Dizon TJR, Hampson K, Daldry S, Hughes J, Brunker K. Lineage BA.2 dominated the Omicron SARS-CoV-2 epidemic wave in the Philippines.. [DOI: 10.1101/2022.05.30.22275783] [Reference Citation Analysis]
|
| 54 |
Gurbaxani BM, Hill AN, Paul P, Prasad PV, Slayton RB. Evaluation of different types of face masks to limit the spread of SARS-CoV-2: a modeling study. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-11934-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 55 |
Akkız H. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern. Front Med 2022;9:849217. [DOI: 10.3389/fmed.2022.849217] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 56 |
Zhou R, Liu N, Li X, Peng Q, Yiu C, Huang H, Yang D, Du Z, Kwok H, Au K, Cai J, Hung IF, To KK, Xu X, Yuen K, Chen Z. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron-BA.2.. [DOI: 10.1101/2022.05.09.491254] [Reference Citation Analysis]
|
| 57 |
Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, Subramoney K, Moyo S, Amoako DG, Baxter C, Althaus CL, Anyaneji UJ, Kekana D, Viana R, Giandhari J, Lessells RJ, Maponga T, Maruapula D, Choga W, Matshaba M, Mayaphi S, Mbhele N, Mbulawa MB, Msomi N, Naidoo Y, Pillay S, Sanko TJ, San JE, Scott L, Singh L, Magini NA, Smith-lawrence P, Stevens W, Dor G, Tshiabuila D, Wolter N, Preiser W, Treurnicht FK, Venter M, Davids M, Chiloane G, Mendes A, Mcintyre C, O’toole A, Ruis C, Peacock TP, Roemer C, Williamson C, Pybus OG, Bhiman J, Glass A, Martin DP, Rambaut A, Gaseitsiwe S, Gottberg AV, de Oliveira T, NGS-SA consortium. Continued Emergence and Evolution of Omicron in South Africa: New BA.4 and BA.5 lineages.. [DOI: 10.1101/2022.05.01.22274406] [Cited by in Crossref: 39] [Cited by in F6Publishing: 46] [Article Influence: 39.0] [Reference Citation Analysis]
|
| 58 |
Björk J, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M, Kahn F. COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022. Euro Surveill 2022;27. [PMID: 35514304 DOI: 10.2807/1560-7917.ES.2022.27.18.2200322] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 59 |
. La pandémie n’est pas finie. Bulletin de l'Académie Nationale de Médecine 2022;206:569-570. [DOI: 10.1016/j.banm.2022.04.004] [Reference Citation Analysis]
|
| 60 |
Atkulwar A, Rehman A, Imaan Y, Baig M. Analyses of Omicron genomes from India reveal BA.2 as a more transmissible variant.. [DOI: 10.1101/2022.04.25.22274272] [Reference Citation Analysis]
|
| 61 |
Ferenčak I, Obrovac M, Žmak L, Kuzle J, Petrović G, Vilibić-čavlek T, Jurić D, Jurić A, Hruškar Ž, Capak K, Stevanović V, Milanović M, Govedarica M, Vujošević D, Tabain I. SARS-CoV-2 Omicron Variant in Croatia—Rapid Detection of the First Case and Cross-Border Spread. Pathogens 2022;11:511. [DOI: 10.3390/pathogens11050511] [Reference Citation Analysis]
|
| 62 |
Chen J, Wei GW. Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant. J Phys Chem Lett 2022;:3840-9. [PMID: 35467344 DOI: 10.1021/acs.jpclett.2c00469] [Cited by in Crossref: 20] [Cited by in F6Publishing: 28] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 63 |
Loconsole D, Centrone F, Sallustio A, Accogli M, Casulli D, Sacco D, Zagaria R, Morcavallo C, Chironna M. Characteristics of the First 284 Patients Infected with the SARS-CoV-2 Omicron BA.2 Subvariant at a Single Center in the Apulia Region of Italy, January–March 2022. Vaccines 2022;10:674. [DOI: 10.3390/vaccines10050674] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 64 |
Gram MA, Emborg H, Schelde AB, Friis NU, Nielsen KF, Moustsen-helms IR, Legarth R, Lam JUH, Chaine M, Malik AZ, Rasmussen M, Fonager J, Sieber RN, Stegger M, Ethelberg S, Valentiner-branth P, Hansen CH. Vaccine effectiveness against SARS-CoV-2 infection and COVID-19-related hospitalization with the Alpha, Delta and Omicron SARS-CoV-2 variants: a nationwide Danish cohort study.. [DOI: 10.1101/2022.04.20.22274061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 65 |
Björk J, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M, Kahn F. COVID-19 vaccine effectiveness against severe disease from the Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022.. [DOI: 10.1101/2022.04.14.22273896] [Reference Citation Analysis]
|
| 66 |
Gjorgjievska M, Mehandziska S, Stajkovska A, Pecioska-dokuzovska S, Dimovska A, Durmish I, Ismail S, Pavlovska T, Stojchevska A, Amedi H, Andonova J, Nikolovska M, Velickovikj S, Mitrev Z, Kungulovski I, Kungulovski G. Case Report: Omicron BA.2 Subvariant of SARS-CoV-2 Outcompetes BA.1 in Two Co-infection Cases. Front Genet 2022;13:892682. [DOI: 10.3389/fgene.2022.892682] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 67 |
Li Q, Zhang M, Liang Z, Zhang L, Wu X, Yang C, An Y, Tong J, Liu S, Li T, Cui Q, Nie J, Wu J, Huang W, Wang Y. Antigenicity comparison of SARS‐CoV‐2 Omicron sublineages with other variants contained multiple mutations in RBD. MedComm 2022;3. [DOI: 10.1002/mco2.130] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 68 |
Ai J, Wang X, He X, Zhao X, Zhang Y, Jiang Y, Li M, Cui Y, Chen Y, Qiao R, Li L, Yang L, Li Y, Hu Z, Zhang W, Wang P. Antibody Resistance of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 Sub-lineages.. [DOI: 10.1101/2022.04.07.487489] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 69 |
Gruell H, Vanshylla K, Korenkov M, Tober-lau P, Zehner M, Münn F, Janicki H, Augustin M, Schommers P, Sander LE, Kurth F, Kreer C, Klein F. Delineating antibody escape from Omicron sublineages.. [DOI: 10.1101/2022.04.06.487257] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 70 |
Marking U, Havervall S, Greilert Norin N, Bladh O, Christ W, Gordon M, Ng H, Blom K, Phillipson M, Mangsbo S, Smed Sörensen A, Nilsson P, Hober S, Åberg M, Klingström J, Thålin C. Correlates of protection, viral load trajectories and symptoms in BA.1, BA.1.1 and BA.2 breakthrough infections in triple vaccinated healthcare workers.. [DOI: 10.1101/2022.04.02.22273333] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 71 |
Zou J, Kurhade C, Xia H, Liu M, Xie X, Ren P, Shi P. Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2.. [DOI: 10.1101/2022.03.30.486409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 72 |
Kirsebom FCM, Andrews N, Stowe J, Toffa S, Sachdeva R, Gallagher E, Groves N, O’connell A, Chand M, Ramsay M, Bernal JL. COVID-19 Vaccine Effectiveness against the Omicron BA.2 variant in England.. [DOI: 10.1101/2022.03.22.22272691] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 73 |
Chen C, Boorla VS, Chowdhury R, Nissly RH, Gontu A, Chothe SK, Labella L, Jakka P, Ramasamy S, Vandegrift KJ, Nair MS, Kuchipudi SV, Maranas CD. A CNN model for predicting binding affinity changes between SARS-CoV-2 spike RBD variants and ACE2 homologues.. [DOI: 10.1101/2022.03.22.485413] [Reference Citation Analysis]
|
| 74 |
Morobe JM, Pool B, Marie L, Didon D, Lambisia AW, Makori T, Mohammed KS, de Laurent ZR, Ndwiga L, Mburu MW, Moraa E, Murunga N, Musyoki J, Mwacharo J, Nyamako L, Riako D, Ephnatus P, Gambo F, Naimani J, Namulondo J, Tembo SZ, Ogendi E, Balde T, Dratibi FA, Ahmed YA, Gumede N, Achilla RA, Borus PK, Wanjohi D, Tessema SK, Mwangangi J, Bejon P, Nokes DJ, Ochola-oyier LI, Githinji G, Biscornet L, Agoti CN. Genomic Epidemiology of SARS-CoV-2 in Seychelles, 2020-2021.. [DOI: 10.1101/2022.03.18.22272503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 75 |
Stolpe M. Impfpflichten, Anreize und die effiziente Nutzung von Coronaimpfstoffen. Wirtschaftsdienst 2022;102:224-8. [DOI: 10.1007/s10273-022-3139-y] [Reference Citation Analysis]
|
| 76 |
Ou J, Lan W, Wu X, Zhao T, Duan B, Yang P, Ren Y, Quan L, Zhao W, Seto D, Chodosh J, Wu J, Zhang Q. Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events.. [DOI: 10.1101/2022.03.13.484129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 77 |
Boldea O, Cornea-madeira A, Madeira J. Disentangling the effect of measures, variants and vaccines on SARS-CoV-2 Infections in England: A dynamic intensity model.. [DOI: 10.1101/2022.03.09.22272165] [Reference Citation Analysis]
|
| 78 |
Xu Z, Zeng Q. More or less deadly? A mathematical model that predicts SARS-CoV-2 evolutionary direction.. [DOI: 10.1101/2022.03.10.483726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 79 |
Peng P, Feng C, Hu J, He C, Deng H, Fan Q, Xiang J, Tang G, Jiang M, Hu F, Li F, Wang K, Tang N, Tang X, Huang A. Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine booster.. [DOI: 10.1101/2022.03.07.483373] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 80 |
Qassim SH, Chemaitelly H, Ayoub HH, Almukdad S, Tang P, Hasan MR, Yassine HM, Al-khatib HA, Smatti MK, Abdul-rahim HF, Nasrallah GK, Al-kuwari MG, Al-khal A, Coyle P, Kaleeckal AH, Shaik RM, Latif AN, Al-kuwari E, Jeremijenko A, Butt AA, Bertollini R, Al-romaihi HE, Al-thani MH, Abu-raddad LJ. Effects of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 Omicron infections.. [DOI: 10.1101/2022.03.02.22271771] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 81 |
Niemann CU, Cunha-bang CD, Helleberg M, Ostrowski SR, Brieghel C. Patients with CLL have similar high risk of death upon the omicron variant of COVID-19 as previously during the pandemic.. [DOI: 10.1101/2022.03.01.22271685] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 82 |
Bartsch YC, Cizmeci D, Kang J, Gao H, Shi W, Chandrashekar A, Collier AY, Chen B, Barouch DH, Alter G. BA.2 evasion of vaccine induced binding and functional non-neutralizing antibodies.. [DOI: 10.1101/2022.02.25.22271511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 83 |
Stegger M, Edslev SM, Sieber RN, Cäcilia Ingham A, Ng KL, Tang ME, Alexandersen S, Fonager J, Legarth R, Utko M, Wilkowski B, Gunalan V, Bennedbæk M, Byberg-grauholm J, Møller CH, Christiansen LE, Svarrer CW, Ellegaard K, Baig S, Johannesen TB, Espenhain L, Skov R, Cohen AS, Larsen NB, Sørensen KM, White ED, Lillebaek T, Ullum H, Krause TG, Fomsgaard A, Ethelberg S, Rasmussen M. Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection.. [DOI: 10.1101/2022.02.19.22271112] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 28.0] [Reference Citation Analysis]
|
| 84 |
Wolter N, Jassat W, von Gottberg A, Cohen C, DATCOV-Gen author group. Clinical severity of Omicron sub-lineage BA.2 compared to BA.1 in South Africa.. [DOI: 10.1101/2022.02.17.22271030] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 85 |
Callaway E. Why does the Omicron sub-variant spread faster than the original? Nature 2022. [PMID: 35177843 DOI: 10.1038/d41586-022-00471-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 30.0] [Reference Citation Analysis]
|
| 86 |
Colson P, Delerce J, Beye M, Levasseur A, Boschi C, Houhamdi L, Tissot-dupont H, Yahi N, Million M, La Scola B, Fantini J, Raoult D, Fournier P. First cases of infection with the 21L/BA.2 Omicron variant in Marseille, France.. [DOI: 10.1101/2022.02.08.22270495] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 87 |
Cao Y, Yisimayi A, Jian F, Xiao T, Song W, Wang J, Du S, Zhang Z, Liu P, Hao X, Li Q, Chen X, Wang L, Wang P, An R, Wang Y, Wang J, Yang P, Sun H, Zhao L, Zhang W, Zhao D, Zheng J, Yu L, Li C, Zhang N, Wang R, Niu X, Yang S, Song X, Zheng L, Li Z, Gu Q, Shao F, Huang W, Wang Y, Shen Z, Wang X, Jin R, Xiao J, Xie XS. Omicron BA.2 specifically evades broad sarbecovirus neutralizing antibodies.. [DOI: 10.1101/2022.02.07.479349] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 88 |
Singh J, Panwar A, Anantharaj A, Rani C, Bhardwaj M, Kumar P, Pargai K, Chattopadhyay P, Devi P, Maurya R, Mishra P, Pandey AK, Pandey R, Medigeshi GR. BA.1 and BA.2 sub-lineages of Omicron variant have comparable replication kinetics and susceptibility to neutralization by antibodies.. [DOI: 10.1101/2022.01.28.22269990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 89 |
Setiabudi D, Sribudiani Y, Hermawan K, Andriyoko B, Nataprawira HM. The Omicron variant of concern: The genomics, diagnostics, and clinical characteristics in children. Front Pediatr 2022;10:898463. [PMID: 35983081 DOI: 10.3389/fped.2022.898463] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 90 |
Barnard RC, Davies NG, Jit M, Edmunds WJ, Centre for Mathematical Modelling of Infectious Diseases COVID-19 working group. Behaviour, booster vaccines and waning immunity: modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era.. [DOI: 10.1101/2021.11.22.21266584] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
